480 related articles for article (PubMed ID: 32061923)
41. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.
Huang J; Liu X; Wei Y; Li X; Gao S; Dong L; Rao X; Zhong J
Front Immunol; 2022; 13():830863. PubMed ID: 35309368
[TBL] [Abstract][Full Text] [Related]
42. Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4.
Lettau M; Dietz M; Vollmers S; Armbrust F; Peters C; Dang TM; Chitadze G; Kabelitz D; Janssen O
Cell Mol Life Sci; 2020 Feb; 77(4):751-764. PubMed ID: 31300870
[TBL] [Abstract][Full Text] [Related]
43. The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury.
Wang XM; Holz LE; Chowdhury S; Cordoba SP; Evans KA; Gall MG; Vieira de Ribeiro AJ; Zheng YZ; Levy MT; Yu DM; Yao TW; Polak N; Jolly CJ; Bertolino P; McCaughan GW; Gorrell MD
Immunol Cell Biol; 2017 May; 95(5):443-453. PubMed ID: 27899813
[TBL] [Abstract][Full Text] [Related]
44. Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.
Wvan der Zanden R; de Vries F; Lalmohamed A; Driessen JH; de Boer A; Rohde G; Neef C; den Heijer C
PLoS One; 2015; 10(10):e0139367. PubMed ID: 26468883
[TBL] [Abstract][Full Text] [Related]
45. CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently.
Klemann C; Schade J; Pabst R; Leitner S; Stiller J; von Hörsten S; Stephan M
Clin Exp Immunol; 2009 Feb; 155(2):357-65. PubMed ID: 19055685
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth.
Hollande C; Boussier J; Ziai J; Nozawa T; Bondet V; Phung W; Lu B; Duffy D; Paradis V; Mallet V; Eberl G; Sandoval W; Schartner JM; Pol S; Barreira da Silva R; Albert ML
Nat Immunol; 2019 Mar; 20(3):257-264. PubMed ID: 30778250
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Amori RE; Lau J; Pittas AG
JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
[TBL] [Abstract][Full Text] [Related]
48. Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration.
Tian Y; Kong L; Li Y; Liao Z; Cai X; Deng S; Yang X; Zhang B; Wang Y; Zhang Z; Wu B; Wen L; Huang F; Hu Y; Wan C; Liao Y; Sun Y; Yang K
Oncoimmunology; 2023; 12(1):2268257. PubMed ID: 37849962
[TBL] [Abstract][Full Text] [Related]
49. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
50. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation.
Zhong J; Rao X; Deiuliis J; Braunstein Z; Narula V; Hazey J; Mikami D; Needleman B; Satoskar AR; Rajagopalan S
Diabetes; 2013 Jan; 62(1):149-57. PubMed ID: 22936179
[TBL] [Abstract][Full Text] [Related]
51. A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells.
Liou JT; Huang HS; Chiang ML; Lin CS; Yang SP; Ho LJ; Lai JH
Eur J Pharmacol; 2014 Mar; 726():124-32. PubMed ID: 24491838
[TBL] [Abstract][Full Text] [Related]
52. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy.
Barreira da Silva R; Laird ME; Yatim N; Fiette L; Ingersoll MA; Albert ML
Nat Immunol; 2015 Aug; 16(8):850-8. PubMed ID: 26075911
[TBL] [Abstract][Full Text] [Related]
53. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
Musoev A; Numonov S; You Z; Gao H
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
[TBL] [Abstract][Full Text] [Related]
54. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
Dokken B
J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
[TBL] [Abstract][Full Text] [Related]
55. Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes.
Jamaluddin JL; Huri HZ; Vethakkan SR; Mustafa N
Pharmacogenomics; 2014 Feb; 15(2):235-49. PubMed ID: 24444412
[TBL] [Abstract][Full Text] [Related]
56. [Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes].
Carramiñana Barrera FC
Semergen; 2018 Jun; 44 Suppl 1():10-17. PubMed ID: 30322468
[TBL] [Abstract][Full Text] [Related]
57. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study.
Bishnoi R; Hong YR; Shah C; Ali A; Skelton WP; Huo J; Dang NH; Dang LH
Cancer Med; 2019 Jul; 8(8):3918-3927. PubMed ID: 31124302
[TBL] [Abstract][Full Text] [Related]
58. Context-dependent effects of dipeptidyl peptidase 4 inhibitors.
Jackson EK
Curr Opin Nephrol Hypertens; 2017 Mar; 26(2):83-90. PubMed ID: 27898522
[TBL] [Abstract][Full Text] [Related]
59. The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus.
Sromova L; Busek P; Posova H; Potockova J; Skrha P; Andel M; Sedo A
Diabetes Res Clin Pract; 2016 Aug; 118():183-92. PubMed ID: 27388675
[TBL] [Abstract][Full Text] [Related]
60. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.
Jang JH; Janker F; De Meester I; Arni S; Borgeaud N; Yamada Y; Gil Bazo I; Weder W; Jungraithmayr W
Carcinogenesis; 2019 Apr; 40(2):324-334. PubMed ID: 30698677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
